Stock Analiz

Anaptysbio, Inc. (ANAB) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Anaptysbio’s revenue went from $17M in fiscal 2016 to $235M in fiscal 2025, growth of about 34.1% a year.

Net income in fiscal 2025 was -$13M, a net margin of -5.6%; the best year in this period was 2016 with -$4M.

Over the twelve months to September 30, 2026, revenue was $192M and net income $184M.

Free cash flow was $20M in fiscal 2025 and positive in 1 of the 10 years shown.

The diluted share count rose 1046% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $17M162017: $10M172018: $5M182019: $8M192020: $75M202021: $63M212022: $10M222023: $17M232024: $91M242025: $235M25$235M
Net income
2016: -$4M162017: -$30M172018: -$62M182019: -$97M192020: -$20M202021: -$58M212022: -$129M222023: -$164M232024: -$145M242025: -$13M25-$13M
Free cash flow
2016: -$9M162017: -$20M172018: -$50M182019: -$70M192020: -$15M202021: -$47M212022: -$74M222023: -$122M232024: -$136M242025: $20M25$20M
EPS (diluted)
2016: $-1.62162017: $-1.52172018: $-2.50182019: $-3.60192020: $-0.73202021: $-2.11212022: $-4.57222023: $-6.08232024: $-4.92242025: $-0.4425$-0.44

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$192M$235M$91M$17M$10M$63M$75M$8M$5M$10M$17M
Gross profit———————————
Operating income$298M$227M$66M-$164M-$115M-$57M-$24M-$107M-$67M-$29M-$3M
Net income$184M-$13M-$145M-$164M-$129M-$58M-$20M-$97M-$62M-$30M-$4M
EPS (diluted)$5.33$-0.44$-4.92$-6.08$-4.57$-2.11$-0.73$-3.60$-2.50$-1.52$-1.62
R&D—$136M$164M$132M$89M$98M$80M$99M$56M$29M$15M
Revenue growth—+157.0%+432.0%+66.8%−83.7%−15.8%+837.5%+60.0%−50.0%−40.1%−5.1%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$36M$20M-$135M-$121M-$74M-$46M-$14M-$70M-$49M-$19M-$9M
Capital spending—-$87000-$358000-$807000-$358000-$1M-$569000-$805000-$1M-$290000-$50000
Free cash flow—$20M-$136M-$122M-$74M-$47M-$15M-$70M-$50M-$20M-$9M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks$3M$69M$456000$50M$0$0——$0$0$1000
Stock-based pay-$12M$4M$7M$33M$27M$15M———$4M$1M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$212M$285M$391M$441M$548M$394M$374M$427M$248M$51M
Debt—$14112$16M$18M$19M$21M$342000$3M$10M$7M$0
Equity—$37M$71M$88M$262M$356M$397M$405M$486M$308M-$38M
Total assets—$364M$484M$452M$610M$643M$417M$435M$509M$329M$62M
Shares (diluted)35M30M30M27M28M27M27M27M25M20M3M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————————
Operating margin155.6%96.7%72.5%-958.3%-1119.4%-89.9%-31.8%-1342.9%-1334.4%-287.8%-18.1%
Net margin96.3%-5.6%-159.1%-953.7%-1251.3%-91.5%-26.6%-1216.7%-1233.1%-300.7%-25.5%
FCF margin—8.4%-148.7%-708.8%-718.9%-74.9%-19.6%-879.0%-991.4%-197.3%-54.4%
ROIC—606.7%75.7%-155.2%-32.3%-15.0%-6.0%-26.3%-13.4%-9.2%—
ROE—-35.6%-204.9%-185.7%-49.1%-16.2%-5.0%-24.0%-12.7%-9.8%11.1%

Frequently asked questions

What is Anaptysbio’s annual revenue?

$235M in fiscal 2025 and $192M over the twelve months to September 30, 2026.

How much profit does Anaptysbio make?

Net income was -$13M in fiscal 2025 (net margin -5.6%).

Is Anaptysbio’s revenue growing?

Yes: revenue rose 157.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.